Cowen Lowers Exagen (NASDAQ:XGN) Price Target to $7.00
Cowen Lowers Exagen (NASDAQ:XGN) Price Target to $7.00
Exagen (NASDAQ:XGN – Get Rating) had its price objective decreased by Cowen to $7.00 in a report released on Thursday, Stock Target Advisor reports. Cowen's price objective would suggest a potential upside of 138.10% from the stock's current price.
據Stock Target Advisor報道，在週四發佈的一份報告中，埃克森美孚(納斯達克：XGN-GET評級)的目標價被考恩下調至7.00美元。考恩的目標價格表明，該股目前的價格可能上漲138.10%。
A number of other research analysts have also recently issued reports on the company. Canaccord Genuity Group reduced their price objective on Exagen from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday. BTIG Research dropped their target price on shares of Exagen from $10.00 to $7.00 and set a "buy" rating for the company in a report on Thursday. KeyCorp lowered shares of Exagen from an "overweight" rating to a "sector weight" rating in a report on Friday, August 5th. Finally, Canaccord Genuity Group dropped their target price on shares of Exagen from $8.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Exagen has an average rating of "Moderate Buy" and an average target price of $9.60.
其他一些研究分析師最近也發佈了關於該公司的報告。週二，Canaccel Genuity Group將Exagen的目標價從8.00美元下調至7.00美元，並在一份研究報告中設定了該股的“買入”評級。BTIG Research在週四的一份報告中將Exagen的目標價從10.00美元下調至7.00美元，並將該公司的評級定為“買入”。KeyCorp在8月5日星期五的一份報告中將Exagen的股票評級從“增持”下調至“行業權重”。最後，Canaccel Genuity Group在週二的一份報告中將Exagen的目標價從8.00美元下調至7.00美元，並將該公司的評級定為“買入”。一位研究分析師對該股的評級為持有，四位分析師對該公司的評級為買入。根據MarketBeat.com的數據，Exagen的平均評級為“中等買入”，平均目標價為9.60美元.
Exagen Stock Down 4.2 %
埃克森美孚股價下跌4.2%
Shares of NASDAQ:XGN opened at $2.94 on Thursday. The stock's 50-day moving average price is $2.92 and its 200-day moving average price is $4.79. Exagen has a 12-month low of $2.10 and a 12-month high of $12.89. The stock has a market capitalization of $47.80 million, a P/E ratio of -1.30 and a beta of 1.17. The company has a current ratio of 9.30, a quick ratio of 9.30 and a debt-to-equity ratio of 0.43.
納斯達克：XGN週四開盤報2.94美元。該股的50日移動均線價格為2.92美元，200日移動均線價格為4.79美元。Exagen的12個月低點為2.10美元，12個月高位為12.89美元。該股市值為4780萬美元，市盈率為-1.30，貝塔係數為1.17。該公司的流動比率為9.30，速動比率為9.30，債務權益比率為0.43。
Institutional Investors Weigh In On Exagen
機構投資者買入Exagen
Exagen Company Profile
Exagen公司簡介
(Get Rating)
(獲取評級)
Exagen Inc develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Exagen Inc.在美國開發和銷售基於其細胞結合補體激活產品技術的各種測試產品，品牌為AVISE。它使風濕科醫生能夠通過自身免疫和自身免疫相關疾病的診斷、預後和監測來護理患者，包括系統性紅斑狼瘡(SLE)和類風濕性關節炎(RA)。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Exagen (XGN)
- MarketBeat: Week in Review 11/14 – 11/18
- Target's Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML's November Rally Have Staying Power?
- 免費獲取StockNews.com關於Exagen的研究報告(XGN)
- MarketBeat：回顧一週11/14-11/18
- 目標的雙重底部可能剛剛得到確認
- 美聯儲能漲到多高？如何進行交易
- Verra移動庫存已返回空間站
- ASML的11月拉力賽有後勁嗎？
Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Exagen Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Exagen和相關公司的最新新聞和分析師評級的每日簡明摘要。
譯文內容由第三人軟體翻譯。